Vericel (VCEL) Q3 2024 earnings summary

Executive summary

• Achieved record third quarter revenue of $57.9M, up 27% year-over-year, with strong growth in both MACI and Burn Care segments.

• Gross margin rose to 72%, and adjusted EBITDA increased 84% to $10.0M for the quarter.

• Net loss narrowed to $0.9M ($0.02/share) from $3.7M ($0.08/share) in Q3 2023, reflecting improved operating leverage.

• FDA approved MACI Arthro for arthroscopic delivery and NexoBrid for pediatric use in Q3 2024; both products launched or expanded in Q3.

• Ended Q3 with $151M in cash and investments, no debt, and strong operating cash flow.

Financial highlights

• Q3 MACI revenue grew 19% to $44.7M; Burn Care revenue rose 66% to $13.2M (Epicel $12.2M, NexoBrid $1.1M).

• Gross profit reached $41.7M (72% of net revenue), up 480 basis points year-over-year.

• Adjusted EBITDA increased 84% to $10M (17% of revenue); YTD Adjusted EBITDA up 103% to $23.6M.

• Q3 operating expenses increased to $44.1M, mainly due to MACI Arthro launch and higher headcount.

• Operating cash flow was $10.2M for Q3 and $36M year-to-date.

Outlook and guidance

• Maintained 2024 revenue guidance of $238–$242M (20–23% growth), implying Q4 revenue of $76–$80M.

• Raised full-year gross margin guidance to 72% (from 71%) and Adjusted EBITDA margin to 22% (from 21%).

• Anticipates strong close to 2024 and sustained high revenue and profit growth in 2025 and beyond, with lower CapEx as new facility construction completes.

• MACI expected to maintain ~20% growth in 2025, with MACI Arthro providing modest initial contribution.

• Burn care growth to remain strong, with NexoBrid and Epicel contributing, but at a more normalized rate.